# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Needham analyst Mike Matson reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $82 price target.
Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR sy...
Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Sil...
The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical's...